Anti‐endothelial cell antibodies in patients with rheumatoid vasculitis

Heurkens, A. H. M.; Daha, Mohamed R.; Breedveld, Ferdinand C.

doi:10.1002/anr.1780320927

Cited by 29 publications

(35 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of AECA has been well documented in diseases in which vascular damage is prominent, such as the connective tissue diseases and vasculitides of various types [7][8][9][10][11][12]16,17]. However, in our diabetic patients they were no more frequent in patients with retinopathy than in those without, and did in fact show a weak negative association with neuropathy and nephropathy as defined for the purpose of the study.…”

Section: Discussionmentioning

confidence: 54%

“…Since the long-term complications of IDDM are due at least in part to microvascular disease, and since anti-endothelial cell antibodies (AECA) are frequently found in diseases such as systemic lupus erythematosus (SLE), systemic sclerosis, rheumatoid vasculitis and microscopic poly-arteritis, in which vascular damage is prominent [7][8][9][10][11][12], it seemed appropriate to ascertain their prevalence in IDDM and their possible association with complications of diabetes. The results described in this report indicate that AECA do occur in IDDM and that they are more common in patients with long-standing diabetes and associated autoimmune disease, but not in patients with diabetic neuropathy, retinopathy or nephropathy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-endothelial cell antibodies in insulin-dependent diabetes mellitus

Wangel

Kontiainen

Scheinin

et al. 1992

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYThe prevalence of IgG class antibodies to endothelial cells (AECA) was studied in 136 young patients with insulin-dependent diabetes mellitus by an enzyme immunoassay using human umbilical cord vein endothelial cells. The patients were divided into four groups according to the time between diagnosis and study and their results were compared with those in control children and blood donors. AECA became progressively more frequent with the duration of diabetes, being 4% in diabetics tested within 2 weeks of diagnosis and reaching 34% after an average disease duration of 11 2 years. They were not more common in patients with neuropathy, retinopathy or nephropathy than in patients without these complications, but were associated with co-existing thyroid disease and IgA deficiency. The results suggest that in insulin-dependent diabetes mellitus AECA are associated with co-existing autoimmune disorders but not with diabetic microvascular disease.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Introductionmentioning

confidence: 99%

Anti-endothelial cell antibodies in insulin-dependent diabetes mellitus

Wangel

Kontiainen

Scheinin

et al. 1992

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…It has been shown that when vasculitis symptoms improve in patients with RA, AECA titers tend to decrease (15). Moreover, high titers of AECA in patients with SLE are associated with an active lesion of the kidney and vasculitis, and it has therefore been suggested that the AECA titer could be used as a measure of renal involvement (16).…”

Section: Aeca Against ␣-Enolase In Behç Et's Disease 2031mentioning

confidence: 99%

Human α‐enolase from endothelial cells as a target antigen of anti–endothelial cell antibody in Behçet's disease

Lee¹,

Chung²,

Kim³

et al. 2003

Arthritis & Rheumatism

175

108

View full text Add to dashboard Cite

Objective. To identify and recombine a protein of the human dermal microvascular endothelial cell (HD-MEC) that specifically reacts with anti-endothelial cell antibody (AECA) in the serum of patients with Behçet's disease (BD), and to evaluate the usefulness of this protein in BD.Methods. The proteomics technique, with 2-dimensional gel electrophoresis and matrix-assisted laser desorption ionization؊time-of-flight (MALDI-TOF) mass spectrometry, was used to identify and recombine HDMEC antigen. Western blotting and enzyme-linked immunosorbent assay (ELISA) of recombinant protein isolated by gene cloning were performed on serum from healthy controls, patients with BD, and patients with other rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, and Wegener's granulomatosis).Results. Eighteen of 40 BD patients had serum IgM antibody to HDMEC antigen. The purified protein that reacted with AECA in BD patient sera was found to be ␣-enolase by 2-dimensional gel electrophoresis followed by immunoblotting and MALDI-TOF mass spectrometry. Recombinant ␣-enolase protein was isolated and refined by gene cloning. On Western blots, AECApositive IgM from the sera of patients with active BD reacted strongly with recombinant human ␣-enolase. BD patient sera positive for anti-␣-enolase did not react with human ␥-enolase. On dot-blotting, reactivity to human ␣-enolase was detected only in the IgM-positive group. Fifteen of the 18 AECA-positive sera that were positive for the HDMEC antigen showed reactivity to recombinant ␣-enolase IgM antibody by ELISA.Conclusion. The ␣-enolase protein is the target protein of serum AECA in BD patients. This is the first report of the presence of IgM antibodies to ␣-enolase in endothelial cells from the serum of BD patients. Although further studies relating this protein to the pathogenesis of BD will be necessary, ␣-enolase and its antibody may prove useful in the development of new diagnostic and treatment modalities in BD.

show abstract

“…High titres of AECA are not detectable in normal controls, whereas they occur in a significant proportion of patients with vasculitic diseases [10][11][12][13] and in a variety of inflammatory disorders which have well defined vasculitic components [14][15][16][17][18][19] including Behçet's disease [20]. The target antigens have not yet been identified but are located on the cell surface, as AECA bind equally well to fixed and unfixed human umbilical vein endothelial cells (HUVEC) [14].…”

Section: Introductionmentioning

confidence: 99%

Raised anti-endothelial cell autoantibodies (AECA), but not anti-neutrophil cytoplasmic autoantibodies (ANCA), in recurrent oral ulceration: modulation of AECA binding by tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ)

Healy

Carvalho

1996

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYRecurrent oral ulceration (ROU) is a common oral mucosal condition of unknown etiology. However, there is evidence to suggest that vasculitis may play a role. Here we investigate the presence in ROU of two autoantibodies associated with vasculitis, AECA and ANCA. AECA target as yet unidentified antigens on the endothelial cell surface and have been identified in patients with vasculitic disorders and inflammatory conditions with a vasculitic component. ANCA target specific neutrophil-associated proteins and are detected in specific vasculitic and chronic inflammatory disorders. AECA and ANCA levels were studied in 20 ROU patients and 20 controls. IgG AECA to the endothelial cell line ECV 304 were detected in 19 ROU patients and four controls. Levels were significantly raised in ROU both to ECV 304 (P < 0 . 000 05) and to human umbilical vein endothelial cells (HUVEC) (P < 0 . 005). Although levels were highest during episodes of ulceration, they were also raised between episodes. Stimulation of endothelial cells with TNF-® significantly increased AECA binding of both ROU (P < 0 . 005) and control samples (P < 0 . 0001), while IFN-°decreased binding (ROU P < 0 . 0001; controls P < 0 . 05). In contrast, ANCA were detected in only one patient and none of the controls. The presence of raised levels of AECA lends support to the hypothesis that a vasculitic process may underlie ROU. Moreover, these findings suggest that endothelial cell expression of AECA target antigens is increased by TNF-® and decreased by IFN-°stimulation.

show abstract

Anti‐endothelial cell antibodies in patients with rheumatoid vasculitis

Cited by 29 publications

References 6 publications

Anti-endothelial cell antibodies in insulin-dependent diabetes mellitus

Anti-endothelial cell antibodies in insulin-dependent diabetes mellitus

Human α‐enolase from endothelial cells as a target antigen of anti–endothelial cell antibody in Behçet's disease

Raised anti-endothelial cell autoantibodies (AECA), but not anti-neutrophil cytoplasmic autoantibodies (ANCA), in recurrent oral ulceration: modulation of AECA binding by tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ)

Contact Info

Product

Resources

About